Vilon vs Cartalax: do you need both peptides

I get asked some version of this question every time someone finds the Khavinson peptide family: if Vilon and Cartalax come from the same research group and work the same basic way, why would you ever run both? Short answer: Vilon and Cartalax target almost entirely different tissue systems, and the case for running both comes down to whether you actually have a reason to touch both systems.

Both are short peptides out of Vladimir Khavinson's lab in St. Petersburg, and both are built on the same core idea, that a very short amino acid sequence can get into a cell nucleus and nudge which genes an aging cell is reading. Past that shared mechanism, they diverge fast.

What each one is actually built to do

Vilon (Lys-Glu) is the immune and thymic member of the family. The in-vitro work shows it driving selective heterochromatin decondensation in aging lymphocytes, which is a fancy way of saying it reopens sections of DNA that had gone quiet with age so the cell can read genes it stopped using (Fedoreyeva et al. 2011, and confirmed in earlier work by Khavinson, Lezhava, and Malinin). That mechanism is the basis for its immune and thymic reputation.

Cartalax (Ala-Glu-Asp) is a different tripeptide entirely, developed from cartilage tissue but studied mostly in fibroblasts, the cells that build and maintain connective tissue broadly: cartilage, tendons, ligaments, skin. In human skin fibroblasts, it activated SIRT-1 and SIRT-6 and stimulated collagen I synthesis, which is a real finding in human-derived cells and not just a rat model. In a separate kidney cell study, it suppressed the senescence markers p16, p21, and p53 while boosting cell proliferation. These are two peptides built for two different jobs, and I don't see the case for calling one a substitute for the other.

The evidence gap between them is real, and it matters

The evidence quality between these two diverges sharply, and sharing a research pedigree doesn't make them equivalent. Vilon has actual human cohort data. Kuznik's group found improved coagulation and immune markers with reduced insulin needs in elderly diabetics, a separate paper found reduced clotting complications in type-1 diabetes, and a case series found better survival in elderly stage-III colorectal cancer patients. That's not a mountain of data, and it's Russian-cohort work that hasn't been independently replicated in the West, but it's human outcomes in sick populations, which is more than most peptides in this space ever get.

Cartalax has zero human trials and zero animal-in-vivo studies. What it has is three in-vitro papers, all from the Khavinson group, covering rat skin fibroblasts, human skin fibroblasts, and rat kidney cells. The lab signals are consistent across those papers, and the human fibroblast finding in particular is a step up from pure animal-cell work, but it's still bench science. Nobody has run this in a person and measured a joint or a skin outcome. If you're deciding where to put your money and your evidence tolerance, Vilon is simply the more mature compound.

I bring this up because I see people assume "same family, same lab, same trust level," and I'd push back on that. I'd treat Vilon as the peptide with an actual track record and Cartalax as the promising but still-preclinical sibling.

Cost, side effects, and who each one actually suits

Side-effect load is mild for both. Vilon's reported adverse events across the Russian literature are occasional injection-site reactions and transient early headache. Cartalax's community and literature reports are injection-site redness and swelling. Neither has a scary safety signal, but Cartalax has one contraindication I won't soften: its mechanism includes p53 suppression alongside increased cell proliferation, and that combination is exactly the profile you don't want to introduce into anyone with active or historical cancer. It has never been studied in oncology patients. If that applies to you, this is a conversation for your oncologist, not a peptide forum.

Cost-wise, both run in the same general range as other Khavinson-family short peptides, cheap per vial compared to something like BPC-157 or a GLP-1, but dosing conventions for Cartalax are genuinely a mess. The Khavinson-school protocol calls for 5 to 10 mcg per day for 10 days, while the community consensus dose is 2 mg per day, which is 200 to 400 times higher, and there is no dose-finding study to say which is closer to right. Vilon's community dosing is more settled, converging around 100 to 200 mcg per day over a 10 to 20 day cycle, repeated two to three times a year, the same short-pulse-then-rest pattern the whole Khavinson family shares.

The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.

Who actually suits each one? If you're dealing with general immune decline or you're drawn to the geroprotective, longevity-adjacent angle and you want the peptide in this family with the strongest human backing, Vilon is the one to look at. If you've got a connective-tissue maintenance interest, aging joints, skin, tendons, and you've already handled the acute-injury side of things, Cartalax is a reasonable long-term add-on, though I'd point out that for active joint injury, BPC-157 and TB-500 still have a far stronger evidence base and track record than anything in the Khavinson family. Neither Vilon nor Cartalax replaces those for acute repair.

As for whether you need both: you need both only if you have two separate goals, immune and thymic support on one side, connective-tissue maintenance on the other. If you only have one of those problems, running the other peptide adds cost and injection burden without a matching reason. That's simply what the tissue targets tell you. For more on how Vilon compares against other family members, the Vilon encyclopedia entry covers where it sits against thymalin and thymosin alpha-1, and the Cartalax entry goes deeper on the dosing discrepancy and the cancer contraindication.

Heads up: OHM has an affiliate relationship with the vendors linked here, so we earn a commission if you buy through one of these links. It costs you nothing extra and it does not change which peptide the evidence supports.

I try to stay evidence-based with peptides, and that means saying plainly that Cartalax is the weaker-evidenced compound of this pair; the family name doesn't buy it the same confidence Vilon has earned.